Skip to main content

Welcome to Janssen United States

VISIT JANSSEN GLOBAL

Janssen Announces U.S. FDA Approval of SPRAVATO (esketamine) CIII Nasal Spray for Adults with Treatment-Resistant Depression (TRD) Who Have Cycled Through Multiple Treatments Without Relief

Mar 05, 2019

TITUSVILLE, N.J.

Janssen Announces U.S. FDA Approval of SPRAVATO^TM (esketamine) CIII Nasal Spray for Adults with Treatment-Resistant Depression (TRD) Who Have Cycled Through Multiple Treatments Without Relief